Based on the above-mentioned, preliminary evidence suggest that a co-expressed profile, for instance lncRNA SOX2-OT and coding gene SOX2 [88], as well as, lncRNA GLI1AS and coding gene GLI1 [90], are probably not only involved in EGFR-TKIs-based therapy resistance mechanisms in lung cancer, but also in epigenetic mechanisms involved in cancer-drug (cisplatinum)-based therapy resistance. The gene discussed is SOX2; the disease is cancer.